Un piéton passe devant l'immeuble de bureaux de l'entreprise pharmaceutique chinoise dans BeiGene Ctiy de Suzhou, Province de Jiangsu en Chine de l'est le 22 novembre

• Contributeur: Cynthia Lee / Alamy Banque D'Images
• ID de l’image: 2AB9BDR
• Taille du fichier: 37,2 MB (1,6 MB Téléchargement compressé)
• Autorisations: Modèle - non | Propriété - non
• Dimensions: 4349 x 2987 px | 36,8 x 25,3 cm | 14,5 x 10 inches | 300dpi
• Date de la prise de vue: 22 novembre 2019

Informations supplémentaires

A pedestrian walks past the office building of Chinese pharmaceutical company BeiGene in Suzhou Ctiy, east China's Jiangsu Province on November 22nd, 2019. A Chinese pharmaceutical company has won market approval from the United States Food and Drug Administration for a self-developed lymphoma drug, marking the first entry of an innovative cancer drug from a Chinese company into the US and giving a boost to domestic drugmakers' ambitions to create new treatments for patients around the world. The drug, known as Brukinsa, is a product from Beijing-based BeiGene. It received the FDA's approval and is expected to become available to US patients by the end of the year, Wu Xiaobin, BeiGene president, said at a news conference.

Recherche dans la banque de photos par tags

• baiji
• beigene
• bioscience
• biotech
• biotechnologie
• china
• chinois
• drogue
• pharmaceutic